Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

BIOGEN Aktie

 >BIOGEN Aktienkurs 
112.65 EUR    -0.4%    (Tradegate)
Ask: 112.65 EUR / 89 Stück
Bid: 112.05 EUR / 89 Stück
Tagesumsatz: 17 Stück
Realtime Kurs von 8 bis 22 Uhr!
BIOGEN Aktie über LYNX handeln
>BIOGEN Performance
1 Woche: +4,3%
1 Monat: -2,7%
3 Monate: +0,4%
6 Monate: -24,0%
1 Jahr: -45,9%
laufendes Jahr: -21,8%
>BIOGEN Aktie
Name:  BIOGEN INC. DL -,0005
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US09062X1037 / 789617
Symbol/ Ticker:  IDP (Frankfurt) / BIIB (NASDAQ)
Kürzel:  FRA:IDP, ETR:IDP, IDP:GR, NASDAQ:BIIB
Index:  S&P500, Nasdaq100
Webseite:  https://www.biogen.com/
Marktkapitalisierung:  16500 Mio. EUR
Umsatz:  8514.44 Mio. EUR
EBITDA:  2670.52 Mio. EUR
Gewinn je Aktie:  7.561 EUR
Schulden:  5739.88 Mio. EUR
Liquide Mittel:  2254.33 Mio. EUR
Umsatz-/ Gewinnwachstum:  6.1% / -38.9%
KGV/ KGV lG:  12.92 / 8.75
KUV/ KBV/ PEG:  1.95 / 1.13 / 6.24
Gewinnm./ Eigenkapitalr.:  15.07% / 9.19%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  BIOGEN
Letzte Datenerhebung:  05.07.25
>BIOGEN Eigentümer
Aktien: 146.53 Mio. St.
f.h. Aktien: 146.16 Mio. St.
Insider Eigner: 0.22%
Instit. Eigner: 92.92%
 >BIOGEN Anleihen 
Es sind 2 Anleihen zur BIOGEN Aktie bekannt.
>BIOGEN Peer Group

 
01.07.25 - 18:15
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease (Zacks)
 
BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies....
30.06.25 - 16:51
Biogen starts phase 3 trial of felzartamab for kidney disease (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.06.25 - 14:01
RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer′s market (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
30.06.25 - 13:33
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy (GlobeNewswire EN)
 
CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure....
27.06.25 - 17:03
Biogen lauds benefits of higher dose Spinraza for spinal muscular atrophy (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.06.25 - 16:03
New Data for Nusinersen Underscore Biogen′s Commitment to Advancing Clinical Research to Improve Outcomes in SMA (GlobeNewswire EN)
 
CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen's applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months....
25.06.25 - 20:31
RBC sees 40% upside in Biogen as pipeline momentum builds (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
25.06.25 - 13:33
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results (GlobeNewswire EN)
 
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for the treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and enable once yearly dosing. An interim analysis of the Phase 1 study in participants with SMA who were previously treated with gene therapy was conducted to inform the decision on whether to move salanersen forward into registrational studies. Both dose levels tested, 40 mg and 80 mg, given once a year, were generally well-tolerated and led to substantial slowing of neurodegeneration, as shown by reductions in neurofilament. Exploratory clinical outcome data shows clinically meaningful improvements in function and attainment of new World Health Organization (WHO) milestones over 1 yea...
18.06.25 - 13:36
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia (GlobeNewswire EN)
 
CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to...
17.06.25 - 04:36
Ihre wichtigsten Termine: Alle Analysten-Augen auf: Biogen, Etsy, Westwing, Bike24, FMC und AdCapital (Wallstreet-Online)
 
Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Jetzt den vollständigen Artikel lesen...
12.06.25 - 21:33
Demystifying Biogen: Insights From 11 Analyst Reviews (Benzinga)
 
Latest Ratings for BIIB DateFirmActionFromTo Mar 2022StifelDowngradesBuyHold Mar 2022RBC CapitalUpgradesSector PerformOutperform Feb 2022Canaccord GenuityMaintainsBuy View More Analyst Ratings for BIIB View the Latest Analyst Ratings read more...
12.06.25 - 18:18
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results (Benzinga)
 
UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care. read more...
12.06.25 - 12:18
Is Biogen Stock Underperforming the S&P 500? (Barchart)
 
Biogen has significantly underperformed the S&P 500 over the past year, but analysts are moderately optimistic about the stock's prospects....
12.06.25 - 08:12
UCB & Biogen: Phase 3 Trial Of Dapirolizumab Pegol In Systemic Lupus Erythematosus Meets Main Goal (AFX)
 
WESTON (dpa-AFX) - UCB (UCB) and Biogen Inc. (BIIB) presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug c......
12.06.25 - 07:03
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity (GlobeNewswire EN)
 
BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology's annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizu...
27.05.25 - 17:30
Biogen and City Therapeutics partner to develop RNAi therapies (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.05.25 - 14:12
Biogen Partners City Therapeutics To Develop Select Novel RNAi Therapies (AFX)
 
WESTON (dpa-AFX) - Biogen Inc. (BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company, announced Tuesday a strategic collaboration to develop select novel RNAi therapies.Th......
27.05.25 - 13:33
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies (GlobeNewswire EN)
 
Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertise Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertise...
22.05.25 - 13:18
Eli Lilly’s Alzheimer’s drug cleared in Australia despite setback for Biogen (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
22.05.25 - 08:51
Aufschlag von 246 Prozent! Sanofi greift nach Alzheimer-Hoffnung (Der Aktionaer)
 
Trotz der Verfügbarkeit des Alzheimer-Medikaments Leqembi (Lecanemab) vom Forschungsduo Eisai respektive Biogen ist der Bedarf an Therapien zur Behandlung der Demenzform weiterhin extrem hoch. Sanofi will sich nun einen Hoffnungsträger gegen Alzheimer unter den Nagel reißen, der sich in der klinischen Entwicklungsphase befindet....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Männer sind wie Luft, zwar versaut, aber unentbehrlich. - Michelle Pfeiffer
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!